Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03767738 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe
A Phase 4 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT03767738 is a Phase 4 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 65 participants.
The verdict
NCT03767738, a Phase 4 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine if the pre-filled syringe (PFS) supports successful preparation and accurate administration of an aflibercept injection. The secondary objective of the study is to assess ocular safety in the study eye.
Interventions
- DRUG Intravitreal Aflibercept Injection (IAI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2020-08-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03767738
The ClinicalTrials.gov registry entry for NCT03767738 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravitreal Aflibercept Injection (IAI) is the first listed.
NCT03767738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03767738 about?
NCT03767738 is a clinical study titled "Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe". The primary objective of the study is to determine if the pre-filled syringe (PFS) supports successful preparation and accurate administration of an aflibercept injection. The secondary objective of the study is to assess ocular safety in the study eye.
What is the current status of trial NCT03767738?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2018-12-19. Estimated completion is 2020-08-19.
What interventions are being tested in trial NCT03767738?
The interventions under investigation include: Intravitreal Aflibercept Injection (IAI) (DRUG).
Who is sponsoring clinical trial NCT03767738?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.